What is CytomX Therapeutics, Inc.'s Shariah compliance score?

CytomX Therapeutics, Inc. (CTMX) has a Shariah compliance score of 66/100 (Grade: B, Acceptable) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does CytomX Therapeutics, Inc. pass AAOIFI screening?

CytomX Therapeutics, Inc. (CTMX) partially passes with caution AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (CTMX: 0.9%), (3) interest-bearing deposits below 30% (CTMX: 28.3%), and (4) prohibited income below 5% (CTMX: 1.9%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for CytomX Therapeutics, Inc. stock?

CytomX Therapeutics, Inc. (CTMX) has a non-permissible income ratio of 1.88%. Muslim investors should purify this percentage of any dividends received and capital gains realized from CTMX shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen CytomX Therapeutics, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for CytomX Therapeutics, Inc. (CTMX) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about CTMX's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is CytomX Therapeutics, Inc. (CTMX) halal? Doubtful. Based on AAOIFI screening, CytomX Therapeutics, Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 66/100 (Grade: B).

CTMX: Is CytomX Therapeutics, Inc. Halal?

Doubtful

CytomX Therapeutics, Inc.

NASDAQHealthcareUS

$3.00

-5.66%

AvoidBorderlineClean

Purify ~1.9% of income

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Sector: Healthcare · Industry: Biotechnology

Why This Stock Is Doubtful

Interest-bearing deposits are 28.3% of market cap, only 1.7 points below the 30% limit

Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 15, 2026

Acceptable

Acceptable but room for improvement

66Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Passed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap0.9% / 30.0%

Compliance History

Doubtfulnow
since Jun 2026
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 15, 2026Fiscal: Q1 2026Source: EDGAR

Purify Your CTMX Dividends

1.9% non-compliant income

CTMX has 1.9% prohibited income. Calculate exactly how much of your dividends to donate.

Financial Overview

Market Cap

482.5M

Price

$3.00

Sector

Healthcare

Industry

Biotechnology

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track CTMX and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is CytomX Therapeutics, Inc. (CTMX) halal to invest in?

CytomX Therapeutics, Inc. (CTMX) is rated Doubtful under AAOIFI Standard 21. It passes the business activity screen but one or more financial ratios are approaching (though not yet exceeding) the AAOIFI thresholds (30% for debt and interest deposits, 5% for prohibited income). Consult a qualified Islamic finance scholar for a personal ruling.

Why did CytomX Therapeutics, Inc. get a B compliance rating?

CytomX Therapeutics, Inc. (CTMX) received a grade of B (Acceptable) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.9% (limit 30%); interest-bearing deposits of 28.3% (limit 30%); prohibited income of 1.88% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change CytomX Therapeutics, Inc.'s Shariah verdict?

CytomX Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is CytomX Therapeutics, Inc. re-screened for Shariah compliance?

CytomX Therapeutics, Inc. (CTMX) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 15, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.